How PBM reforms could push drugmakers into the pricing spotlight

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. For over a decade, pharmacy benefit managers have been in the hot seat, absorbing the bulk of Washington's bipartisan scrutiny over rising prescription drug costs. Now, the pricing pendulum is swinging back in pharma’s direction. Sweeping reforms in the Consolidated Appropriations Act of 2026, signed into law by President Donald Trump earlier this month, included ch ...